Centessa Pharmaceuticals PLC Sponsored ADR $CNTA Shares Acquired by Cutter Capital Management LP

Key Points

• Cutter Capital Management LP has significantly increased its stake in Centessa Pharmaceuticals by 184.3%, owning 418,127 shares worth approximately $6 million as of their latest SEC filing.
• Institutional investors now hold 82.01% of Centessa Pharmaceuticals, showcasing strong interest from large investors, while recent performance has led to price upgrades and target price forecasts from several research analysts.
• Centessa Pharmaceuticals reported a quarterly earnings loss of ($0.38) EPS, missing estimates, and its stock currently has a consensus buy rating with a price target of $31.45.

Cutter Capital Management LP raised its position in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Free Report) by 184.3% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 418,127 shares of the company's stock after buying an additional 271,051 shares during the quarter. Centessa Pharmaceuticals comprises about 2.6% of Cutter Capital Management LP's holdings, making the stock its 19th largest position. Cutter Capital Management LP owned approximately 0.31% of Centessa Pharmaceuticals worth $6,013,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in CNTA. Barclays PLC boosted its holdings in shares of Centessa Pharmaceuticals by 1,414.9% in the fourth quarter. Barclays PLC now owns 5,302 shares of the company's stock valued at $89,000 after acquiring an additional 4,952 shares in the last quarter. Voya Investment Management LLC purchased a new position in shares of Centessa Pharmaceuticals during the 4th quarter worth approximately $497,000. The Manufacturers Life Insurance Company lifted its holdings in shares of Centessa Pharmaceuticals by 19.8% in the 4th quarter. The Manufacturers Life Insurance Company now owns 317,329 shares of the company's stock valued at $5,315,000 after buying an additional 52,360 shares during the period. Ameriprise Financial Inc. acquired a new stake in shares of Centessa Pharmaceuticals in the 4th quarter valued at approximately $320,000. Finally, BNP Paribas Financial Markets purchased a new stake in shares of Centessa Pharmaceuticals in the fourth quarter valued at approximately $162,000. Institutional investors and hedge funds own 82.01% of the company's stock.

Centessa Pharmaceuticals Price Performance

Centessa Pharmaceuticals stock traded up $1.58 during midday trading on Tuesday, reaching $19.61. 1,107,355 shares of the company were exchanged, compared to its average volume of 991,181. The company has a market capitalization of $2.63 billion, a price-to-earnings ratio of -11.07 and a beta of 1.47. The company has a debt-to-equity ratio of 0.32, a quick ratio of 10.12 and a current ratio of 10.11. The firm's 50-day simple moving average is $16.09 and its 200-day simple moving average is $14.44. Centessa Pharmaceuticals PLC Sponsored ADR has a 1 year low of $9.60 and a 1 year high of $19.99.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.03). On average, analysts anticipate that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 EPS for the current year.

Insider Activity

In other Centessa Pharmaceuticals news, CEO Saurabh Saha sold 55,000 shares of the business's stock in a transaction on Monday, July 21st. The stock was sold at an average price of $15.92, for a total value of $875,600.00. Following the completion of the transaction, the chief executive officer directly owned 221,017 shares in the company, valued at approximately $3,518,590.64. The trade was a 19.93% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Mario Alberto Accardi sold 8,322 shares of the stock in a transaction on Tuesday, July 29th. The stock was sold at an average price of $15.23, for a total value of $126,744.06. Following the transaction, the insider directly owned 208,163 shares in the company, valued at approximately $3,170,322.49. This represents a 3.84% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 171,322 shares of company stock valued at $2,472,814 over the last quarter. Insiders own 7.09% of the company's stock.

Analyst Upgrades and Downgrades

CNTA has been the subject of a number of recent analyst reports. Wells Fargo & Company initiated coverage on Centessa Pharmaceuticals in a report on Wednesday, September 3rd. They issued an "overweight" rating and a $31.00 target price for the company. Oppenheimer assumed coverage on shares of Centessa Pharmaceuticals in a report on Friday, August 29th. They set an "outperform" rating and a $40.00 price objective on the stock. Needham & Company LLC assumed coverage on shares of Centessa Pharmaceuticals in a research report on Wednesday, May 28th. They set a "buy" rating and a $35.00 target price on the stock. Chardan Capital reiterated a "buy" rating and set a $30.00 price target on shares of Centessa Pharmaceuticals in a research report on Tuesday, August 12th. Finally, Wall Street Zen cut Centessa Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Saturday, August 16th. One research analyst has rated the stock with a Strong Buy rating and twelve have issued a Buy rating to the company's stock. Based on data from MarketBeat, Centessa Pharmaceuticals presently has a consensus rating of "Buy" and a consensus price target of $31.45.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.